Cargando…
Single-dose rifampicin chemoprophylaxis protects those who need it least and is not a cost-effective intervention
Autores principales: | Lockwood, Diana N. J., Krishnamurthy, Padebettu, Kumar, Bhushan, Penna, Gerson |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991657/ https://www.ncbi.nlm.nih.gov/pubmed/29879118 http://dx.doi.org/10.1371/journal.pntd.0006403 |
Ejemplares similares
-
Leprosy postexposure prophylaxis with single-dose rifampicin: Nepalese dermatologist’s dilemma
por: Parajuli, Niraj, et al.
Publicado: (2021) -
Venous Thromboembolism Risk Stratification and Chemoprophylaxis: A Meta-Analysis Finds No Benefit, More Risk
por: Swanson, Eric
Publicado: (2017) -
Trend analysis of leprosy in Morocco between 2000 and 2017: Evidence on the single dose rifampicin chemoprophylaxis
por: Khoudri, Ibtissam, et al.
Publicado: (2018) -
An innovative approach to screening and chemoprophylaxis among contacts of leprosy patients in low endemic settings: experiences from Cambodia
por: Cavaliero, Arielle, et al.
Publicado: (2019) -
It’s All about Those Bases: The Need for Incorporating Parasite Genetic Heterogeneity into the Development of Schistosome Vaccines
por: Gleichsner, Alyssa M., et al.
Publicado: (2015)